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Abstract
Objective: Adolescents and young adults (AYAs) diagnosed with cancer commonly
experience elevated psychological distress and need appropriate detection and
management of the psychosocial impact of their illness and treatment. This paper
describes the multinational validation of the Distress Thermometer (DT) for AYAs
recently diagnosed with cancer and the relationship between distress and patient
concerns on the AYA‐Needs Assessment (AYA‐NA).
Methods: AYA patients (N = 288; 15–29 years, Mage = 21.5 years, SDage = 3.8) from
Australia (n = 111), Canada (n = 67), the UK (n = 85) and the USA (n = 25)
completed the DT, AYA‐NA, Hospital Anxiety Depression Scale (HADS) and de-
mographic measures within 3 months of diagnosis. Using the HADS as a criterion,
receiver operating characteristics analysis was used to determine the optimal cut‐
off score and meet the acceptable level of 0.70 for sensitivity and specificity. Cor-
relations between the DT and HADS scores, prevalence of distress and AYA‐NA
scores were reported.
Results: The DT correlated strongly with the HADS‐Total, providing construct
validity evidence (r = 0.65, p < 0.001). A score of 5 resulted in the best clinical
screening cut‐off on the DT (sensitivity = 82%, specificity = 75%, Youden In-
dex = 0.57). Forty‐two percent of AYAs scored at or above 5. ‘Loss of meaning or
purpose’ was the AYA‐NA item most likely to differentiate distressed AYAs.
Conclusions: The DT is a valid distress screening instrument for AYAs with cancer.
The AYA‐POST (DT and AYA‐NA) provides clinicians with a critical tool to assess
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the psychosocial well‐being of this group, allowing for the provision of personalised
support and care responsive to individuals' specific needs and concerns.
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1 | BACKGROUND
Adolescent and young adult (AYA1) cancer patients have been recog-
nised as a distinct group with specific needs and concerns since the
mid‐1990s.1 Internationally, it is estimated there are over a million new
cases of cancer amongst AYAs each year,2 and due to their relative high
survival rates and long life expectancy, theburden of cancer for this age
group is greater for both the individual and society than any other.3 As
a consequence of this need, services have been established to provide
holistic cancer care specifically to AYA patients.4–8
The considerable psychological impact of cancer on the
diagnosed individual and their family and friends has been well
documented.9–11 Thus, routine distress screening was recommended
by the National Comprehensive Cancer Network (NCCN) in 2007,
along with the development of a distress screening tool for adults
with cancer; the NCCN Distress Thermometer (DT) and Problem
Checklist (PCL).12 The DT is a single‐item, self‐report measure of
distress with an 11‐point scale (0–10).13 The PCL is a checklist of
potential causes of distress grouped within domains, and patients
endorse their specific concerns.14
AYAs have been found to have high levels of distress at diag-
nosis, during treatment and for many years post treatment.15,16 In
2011, in response to an identified need for an age appropriate
screening tool, the AYA Oncology Psychosocial Care Manual17 was
developed, describing best practice in psychosocial screening,
assessment and care planning for AYA cancer patients. No distress
screening tool had been validated across the AYA age range18 and
the NCCN DT and PCL was chosen as the preferred tool following
modification for the AYA population.5 Palmer et al.5 with input from
AYA patients and survivors, and AYA cancer healthcare pro-
fessionals, adapted the PCL to be more developmentally appropriate
for AYA. This adapted PCL was called the AYA Needs Assessment
(AYA‐NA). Adaptations included both the addition and removal of
items and domains. For example, in the family domain, items of ‘Mum
and/or dad’ and ‘Brother(s) and/or Sister(s)’ were added. Items were
also added to the emotional domain to reflect how AYAs often ex-
press distress (e.g., Boredom, Moodiness, Confusion) and in the
physical domain ‘Hair loss’ was added, and ‘Indigestion’ was removed.
Furthermore, two new domains (social and information) were added to
account for the AYA experience, for example ‘Isolated from friends',
‘Missing important events’ and ‘Feeling involved in decision making’.
This AYA distress screening tool (comprising the DT and AYA‐NA)
became known as the Adolescent and Young Adult Psycho‐Oncology
Screening Tool2 (AYA‐POST17) and was identified as a promising
measure of distress in a 2014 review of psychosocial measures
available for AYAs with cancer.18
The NCCN DT and PCL version has been extensively validated
with adult cancer populations.13 Further, Recklitis et al.19 examined
the use of the DT with adults 18–40 year olds who had completed
treatment (mean age: 29 years) and Chan et al.20 reported using the
DT in Asian AYAs, finding a cut‐off of 4 was significantly associated
with worry, depressed mood and nervousness. Chan et al.20 also
reported testing the original adult PCL with AYAs, finding that re-
lationships existed between endorsement of checklist items and
distress. However, no investigation of the optimal cut‐off on the DT
for recently diagnosed AYAs or of the appropriateness of the
AYA‐NA has been undertaken to date.
A meta‐analysis by Ma et al.13 found that approximately three‐
quarters of validation studies of the DT used the Hospital Anxiety
and Depression Scale (HADS)21 as a criterion, and, concluded that a
score of 4 or higher is the optimal screening cut‐off for further
assessment.13 Of the 42 included studies in this analysis, 30 (71.4%)
compare the DT to the HADS. Of these 30 studies, 13 (43.3%)
identify 4 as being the optimal cut‐off score and 7 (23.3%) identify 5
as being the optimal cut‐off score.
A large study was developed to evaluate the clinical utility of the
AYA‐POST, validate the DT, report the endorsement of the AYA‐NA
and measure the prevalence and predictors of distress amongst
AYAs. The protocol for this study has been reported previously.22
Given the significant international interest in the AYA‐POST, certain
aspects of the larger study were completed collaboratively across
countries with participants from the USA, Canada and UK. This paper
reports on this multinational work. Given the variation in ages
considered to be AYA internationally,23 the authors selected an age
range of 15–29 years as it encompasses the whole age range typically
used in the UK (15–24 years) and Australia (15–25 years), and much of
the age range typically used in North America (15–39 years).
This paper reports on aspects of the validation of the AYA‐POST.
The main aim of this paper is to report the optimal cut‐off score on the
DT for AYAs aged 15–29 years that balances sensitivity and specificity,
using the HADS as a criterion. As mentioned above, the HADS is the
most common criterion in validations of the DT,13 and is validated with
both adults and adolescents.24,25 Secondarily, we estimate the preva-
lence of distress amongst AYAs, examine the relationship between
distress scores and AYA‐NA responses, and describe the endorsement
of items in the AYA‐NA including determining whether any items are
redundant and the usefulness of items added to reflect the concerns of
AYAs.
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2 | METHOD
2.1 | Participants
A total of 288 AYA (aged 15–29 years) cancer patients within 3
months of diagnosis were recruited from 28 cancer centres in
Australia, Canada, UK and the USA (Mage = 21.5 years; SDage = 3.8;
range: 15–29; 25%: 15–19 years, 64%: 20–25 years, 11%: 26–29
years). The demographics and characteristics of the sample are pre-
sented in Table 1.
2.2 | Ethics
Ethics was obtained at the following lead sites within Australia: the
Prince of Wales Hospital (HREC/14/POWH/261), Northern Territory
TAB L E 1 The demographics and cancer‐related characteristics of the AYA cancer patients from Australia, Canada, UK and USA
Australia (n = 111) Canada (n = 67) UK (n = 85) USA (n = 25) Total (n = 288)
M (SD) M (SD) M (SD) M (SD) M (SD)
Age at diagnosis 20.2 (3.1) 22.6 (4.2) 19.8 (2.6) 24.4 (3.0) 21.5 (3.8)
Frequency (%) Frequency (%) Frequency (%) Frequency (%) Frequency (%)
Gender Female 54 (48.6) 28 (41.8) 34 (40.0) 14 (56.0) 130 (45.1)
Male 57 (51.4) 39 (58.2) 51 (60.0) 11 (44.0) 158 (54.9)
Diagnosis Lymphoma 37 (33.3) 16 (23.9) 30 (35.3) 1 (4.0) 84 (29.2)
Leukaemia 21 (18.9) 13 (19.4) 14 (16.5) 7 (28.0) 55 (19.1)
Germ cell cancer 15 (13.5) 15 (22.4) 17 (20.0) 4 (16.0) 51 (17.7)
Sarcoma 17 (15.3) 9 (13.4) 12 (14.1) 6 (24.0) 44 (15.3)
Carcinoma 6 (5.4) 13 (19.4) 8 (9.4) 4 (16.0) 31 (10.8)
Brain and CNS 5 (4.5) 00 (0.0) 2 (2.4) 00 (0.0) 7 (2.4)
Other cancer 8 (7.2) 16 (23.9) 2 (2.4) 3 (12.0) 29 (10.1)
Unsure 5 (4.5) 1 (1.5) 00 (0.0) 00 (0.0) 6 (2.1)
Education Still in high school 24 (21.6) 10 (14.9) 10 (11.8) 2 (8.0) 46 (16.0)
Finished high school 20 (18.0) 14 (20.9) 1 (1.2) 10 (40.0) 45 (15.6)
Still in college or university 41 (36.9) 11 (16.4) 25 (29.4) 10 (40.0) 87 (30.2)
Finished college or university 26 (23.4) 32 (47.8) 1 (1.2) 3 (12.0) 62 (21.5)
Missing 00 (0.0) 00 (0.0) 48 (56.5) 00 (0.0) 48 (16.7)
Working Yes 35 (31.5) 23 (34.3) 34 (40.0) 14 (56.0) 106 (36.8)
Living with parents/other
family members
Yes 81 (73.0) 55 (82.1) 63 (74.1) 15 (60.0) 214 (74.3)
Living with partner Yes 25 (22.5) 7 (10.4) 10 (11.8) 5 (20.0) 47 (16.3)
Living with housemate/
close friends
Yes 13 (11.7) 3 (4.5) 4 (4.7) 3 (12.0) 23 (8.0)
Treatment status Diagnosed but haven't
started treatment
12 (10.8) 00 (0.0) 6 (7.1) 5 (20.0) 23 (8.0)
Commenced treatment 96 (86.5) 59 (88.1) 79 (92.9) 15 (60.0) 249 (86.5)
Unsure 3 (2.7) 00 (0.0) 00 (0.0) 00 (0.0) 3 (1.0)
Missing 00 (0.0) 8 (11.9) 00 (0.0) 5 (20.0) 13 (4.5)
Treatments received Chemotherapy 86 (77.5) 48 (71.6) 62 (72.9) NP 196 (68.1)
Radiation therapy 6 (5.4) 4 (6.0) 3 (3.5) NP 13 (4.5)
Surgery 28 (25.2) 12 (17.9) 19 (22.4) NP 59 (20.5)
Other treatments 2 (1.8) 00 (0.0) 2 (2.4) NP 4 (1.4)
Unsure 3 (2.7) 1 (1.5) NP NP 4 (1.4)
Abbreviation: NP, not provided.
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Department of Health and Menzies School of Health Research
(HREC‐2014‐2295), Children's Health Queensland Hospital and
Health Service (HREC/14/QRCH/374), Women's and Children's
Hospital (HREC/14/WCHN/113), Peter MacCallum Cancer Centre
(14/178), Sir Charles Gairdner (2015‐048) and ACT Health
(ETH.11.14.331) Human Research Ethics Committees. Within Can-
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participating institution including Princess Margaret Cancer Centre
(PMCC) (Toronto, Ontario), McMaster Children's Hospital (Hamilton,
Ontario), Alberta Children's Hospital (Edmonton, Alberta) and British
Columbia (BC) Women's and Children's Hospital (Vancouver, BC).
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approval (14/WS/1009) and in the USA, the USC Health Sciences
Institutional Review Board; Office for the Protection of Research
Subjects; University of Southern California gave approval for proto-
col number HS‐15‐00651.
2.3 | Measures
2.3.1 | Adolescent & Young Adult Psychosocial
Oncology Screening Tool
The AYA‐POST consists of the DT and the AYA‐NA:
The DT is a ‘thermometer’ presenting numbers vertically from 0 to
10. People rate their distress over the last week with 0 indicating ‘no
distress’ and 10 indicating ‘high distress’. It is consistent with the
original NCCN version.14
The AYA‐NA is a list of specific concerns that could contribute to
distress for AYA cancer patients and may provide healthcare pro-
fessionals with specific biopsychosocial issues to address. The list was
developed with experienced AYA clinicians and AYAs with a cancer
experience, providing good content validity.5 Table 2 provides a
complete list of items as presented in the tool, grouped into six do-
mains: practical, family, emotional, physical, social and information.
2.3.2 | Hospital Anxiety and Depression Scale
The HADS is a widely used 14‐item measure, to estimate anxiety,
depression and general distress. It was originally validated for use
with people aged 16–65 years21 and the most widely used HADS‐
Total cut‐off score in DT validation studies is 15 indicating clinical
levels of distress. Since then it has been validated in adolescents aged
12–17 years,25 identifying cut‐off scores of 9 and 7 to indicate
clinical levels on the Anxiety and Depression subscales respectively.
2.4 | Statistical analysis
Receiver operator characteristic (ROC) analysis26 was used to
determine a suitable cut‐off for the DT Score. The aim was to
maximise sensitivity (true positive rate) and specificity (true negative
rate) to detect individuals with a HADS total score of 15 or higher; a
minimum of 0.70 for sensitivity and specificity was considered to be
indicative of a valid psychological screening tool.27,28 Sensitivity is
primary for a screening tool, as specificity can be compensated for
in care provision following screening.28 Youden's Index was also
calculated to integrate sensitivity and specificity. The area under the
curve (AUC) was calculated as an additional index of test accuracy.
Analyses were run using three different criteria: a score of 7 on
the HADS‐Depression25; a score of 9 on the HADS‐Anxiety25; and a
score of 15 on the HADS‐Total.
Analyses on the AYA‐NA included data from all countries except
Canada, who used a different approach in their checklist.29 Fre-
quencies of endorsement for individual items and domains were
described. Chi square tests were performed to identify whether
there were significant differences in how distressed and non‐
distressed participants endorsed individual items and domains. A
Bonferroni correction for multiple analyses was applied to the chi‐
square tests to maintain a familywise error rate of ≤0.05
(α = 0.05/50 = 0.001).
2.5 | Procedure
Participants were eligible if they were within the AYA age range
at their hospital,3 had been diagnosed with cancer within the
last 3 months and were judged as able to complete the survey
(e.g., had adequate English and were not in intensive palliative
care). Most participants completed the survey whilst at the
relevant hospital, however some were given the option of
completing it at home. The survey was completed on paper
everywhere except in Canada where it was completed online. A
participant information sheet was provided, and informed consent
obtained.
3 | RESULTS
3.1 | DT and HADS scores
The mean DT score was 3.93 (SD = 2.36), the mean HADS
scores were 11.04 (SD = 6.61) for the HADS‐Total, 6.24
(SD = 4.20) for the HADS‐Anxiety and 4.80 (SD = 3.53) for the
HADS‐Depression. The Pearson correlation between DT score and
HADS‐Total scores was large and positive, (r = 0.65, p < 0.001), as
were the correlations between DT score and HADS‐Anxiety score
(r = 0.65, p < 0.001) and HADS‐Depression score (r = 0.48,
p < 0.001).
3.2 | Determining the DT cut‐off score
ROC analysis for HADS‐Total, HADS‐Anxiety and HADS‐Depression
are depicted in Figure 1.
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TAB L E 2 For participants from Australia, UK and the USA: The proportion endorsing at least 1 need per AYA‐NA domain, the average







presented in the tool) % Yes
Practical (5 items) (N = 219) 67.6% 24.1% (23.2)0%–100% Housing or living arrangements 14.6
Educationc 34.7
Work or careerc 28.8
Transport or parking 13.7
Bills or finances 28.8
Family (5 items) (N = 219) 49.8% 17.4% (21.7)0%–100% Mum and/or dadc 32.4
Brother(s) and/or sister(s) c 23.3
Partner, boyfriend or girlfriendc 16.0
Child (ren) 4.1
Other family membersc 11.4
Emotional (11 items) (N = 219) 78.5% 20.1% (19.2)0%–91% Sadness 28.3
Feeling alone or isolatedc 16.4
Anxiety or fear 33.3
Guiltc 11.0
Boredomc 46.1
Anger or frustrationc 25.1
Extreme moodinessc 12.3
Feeling hopeless or helplessc 16.4
Feeling confusedc 18.7
Loss of meaning or purposec 10.0
Loss of faith or spirituality 3.2
Social (5 items) (N = 134a) 69.4% 25.2% (22.3)0%–100% Isolated from friendsc 17.9
Missing important eventsc 32.1
Friends don't understandc 6.0
Worry about boy/girlfriendc 21.1
Missing doing the ‘normal stuff’ with friendsc 49.3
Physical (19 itemsb) (N = 219) 84.9% 19.8% (17.0)0%–89% General appearance 26.9
Hair lossc 38.4
Breathing difficulty 12.3
Fitness or sporting abilityc 29.2
Sleeping difficulty 33.3
Constipation or diarrhoea 22.8
Sexual concerns 10.0
Loss of libidob,c 9.7
Pain when having sexb,c 4.5
Fertilityc 19.6
Eating or appetite 29.2
Extreme exhaustion or tirednessc 28.8
Memory or concentration 18.7
(Continues)
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Using the HADS‐Total criterion, optimal sensitivity (0.82) and
specificity (0.75) were achieved for a DT score of 5 (Youden's
J = 0.57, AUC = 0.84, 95% CI = 0.79–0.89). The DT score of 5
was also optimal for the HADS‐Anxiety subscale clinical cut‐off
(sensitivity = 0.71, specificity = 0.81, Youden's J = 0.52,
AUC = 0.81, 95% CI = 0.76–0.87; see Figure 1) and the HADS‐
Depression subscale clinical cut‐off (sensitivity = 0.84, speci-
ficity = 0.68, Youden's J = 0.52, AUC = 0.81, 95% CI = 0.75–0.88;
see Figure 1). Results for all DT scores are provided in supporting
materials.
3.3 | Rates of distress
Using the cut‐off of 5 on the DT, the overall rate of distress was 41.5%.
There were higher rates of distress in females (53.8%) than males
(31.2%; χ2 = 15.11, df = 1, p < 0.001), and in older than younger AYAs
(20–29 years: 46.4%; 15–19 years: 29.7%; χ2 = 5.673, df= 1, p= 0.017).
Rates of distress differed between countries (χ2 = 9.012, df = 3,
p = 0.029). The proportion of participants with clinically elevated
distress by DT score of 5 or more was 25.4% in Canada, 42.4% in the
UK, 47.2% in Australia and 48.0% in the USA.
F I GUR E 1 ROC curve for the HADS‐Total, HADS‐Anxiety and HADS‐Depression scores, using a DT cut‐off score of 5







presented in the tool) % Yes
Tingling in hands or feet 11.9
Pain 21.9
Nausea or vomiting 26.9
High temperature or fever 11.4
Use of alcohol and/or drugsc 4.6
Other medical worryc 6.9
Information (5 items) (N = 219) 28.3% 8.3% (15.6)0%–100% Understanding of informationc 20.5
Feeling involved in decision makingc 6.8
Feeling listened toc 7.8
Rights to confidentialityc 1.8
Rights to privacyc 4.6
aParticipants from the UK were not included in the social domain, as they used a different version of this subscale.
bParticipants from the UK completed the 17‐item, paediatric version of the AYA‐NA which excludes 2 items on sexual functioning in the physical
domain.
cItems that are new or modified (cf. the adult version).
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Almost every AYA (95.9% of participants) reported at least one
concern on the AYA‐NA. Additionally, 41.1% reported 10 or more
concerns: this included 49.5% of Australian AYAs (N = 109); 36.0% of
USA participants (N = 25) and 31.8% of UK participants (N = 85).
Endorsement of domains and individual items are in Table 2. Par-
ticipants were most likely to endorse at least one physical concern
(84.9%), emotional concern (78.5%), social concern (69.4%) or prac-
tical concern (67.6%). The most frequently endorsed items were
‘Missing doing the “normal stuff” with friends’ (49.3%), ‘Boredom’
(46.1%), ‘Hair loss’ (38.4%), ‘Education’ (34.7%), ‘Anxiety or fear’
(33.3%), ‘Sleeping difficulty’ (33.3%) and ‘Mum and/or dad’ (32.4%).
3.4 | Associations between AYA‐NA items and
distress
Distressed participants tended to endorse AYA‐NA items to a
greater extent than non‐distressed participants, overall: 67% of dis-
tressed participants reported 10 or more concerns, compared to 20%
of non‐distressed participants. Chi‐square analyses indicated that
distressed participants endorsed 12 of the AYA‐NA items signifi-
cantly more frequently than non‐distressed participants. These items
were from the emotional, social and physical domains (see Table 3 for
details).
4 | DISCUSSION
This paper provides the first validation of the DT as a distress
screening tool with AYAs recently diagnosed with cancer, sup-
porting its use with this cohort. Since its development, requests to
use the AYA‐POST have come from 20 countries in five continents
demonstrating the need for a specific distress screening tool for
this age group. This multinational study supports clinicians and
researchers using the AYA‐POST, with a distinct age‐appropriate
cut‐off on the DT to identify AYAs for further assessment. Addi-
tionally, our study presents striking information on the high
distress rates and many concerns of AYAs with cancer while also
observing some variation between participants from different
countries.
We identified firm evidence for the DT's convergent validity by
correlation with all HADs scales, and AYAs who were identified as
distressed reported more concerns on the AYA‐NA. The ROC ana-
lyses consistently indicated that a DT cut‐off score of 5 and above
provided acceptable specificity and sensitivity scores to constitute a
positive screen and undertake further detailed assessment. As pre-
viously mentioned, a meta‐analysis13 showed seven (23.3%) DT
validation studies with adult populations identified an optimal cut‐off
of 5. Focusing on young adults, Recklitis et al.19 examined the validity
of the DT using a standardised clinical interview as a reference cri-
terion. They found that a DT cut‐off of 5 had a sensitivity of 68.2%
and a specificity of 78.3% to detect a psychiatric diagnosis, though it
should be noted that their sample comprised cancer survivors who
were at least 2 years off treatment with an age range of 18–40 years.
Using the DT cut‐off of 5, 41.5% of AYAs in our study reported
elevated levels of distress. We found that older AYAs were more
likely to reach criterion for distress than younger AYAs, as did Chan
et al.20 As has been reported in adults,30 more females than males
met the criterion for distress in this study. The mean score of 3.93 on
the DT in this study is consistent with Chan et al.20 in 24–39 year
olds (3.7–3.8), but higher than they reported for 15–24 year olds
(2.7–2.8).
TAB L E 3 Prevalence of AYA‐NA item endorsement amongst distressed and non‐distressed AYAs
Domain AYA‐NA item
Proportion of group endorsing item
Odds ratioa χ2Distressed Non‐distressed
Emotional Sadness 47% 13% 6.09 31.27
Feeling alone or isolated 29% 6% 7.62 20.89
Anxiety or fear 53% 16% 5.88 33.32
Guilt 18% 4% 4.96 10.86
Boredom 38% 14% 1.42 15.97
Extreme moodiness 22% 4% 6.37 15.74
Feeling confused 29% 9% 3.97 13.99
Loss of meaning or purpose 19% 3% 8.99 16.16
Social Isolation from friends 29% 7% 5.40 11.307
Physical Sleeping difficulty 48% 21% 3.43 17.473
Extreme exhaustion or tiredness 42% 17% 3.55 16.690
Memory or concentration 28% 10% 3.44 11.486
Note: Only items with a significant (p < 0.001) χ2 tests are shown.
aOdds ratio shows the odds that a patient will be classified as distressed on the DT if they endorse that AYA‐NA item.
PATTERSON ET AL. - 7
Rates of distress varied between countries, with Canadian par-
ticipants reporting lower levels of distress. While it is possible that
there are baseline differences in distress between the countries,
previous research has found that rates of anxiety and depression
amongst adolescents in Western countries is similar.31 Exploratory
secondary analysis (not reported) suggests that the differences found
here may be partially explained by demographic differences between
the samples such as the Canadian sample having a lower proportion
of females and a higher proportion living with their parents.
Many concerns were reported by the study participants and all
items were endorsed by at least some participants. Given this, no
AYA‐NA items were considered redundant. Over 40% of AYAs
endorsed at least 10 of the items, with 2 in every 3 who were dis-
tressed reporting 10 concerns or more. Across all the study partici-
pants, 96% endorsed at least 1 item. We observed support for the
modifications made to the PCL in the development of the AYA‐NA, as
the most endorsed items (both overall and by distressed participants)
were not present in the PCL. The most endorsed items included those
added to the AYA‐NA: ‘Missing doing the “normal stuff” with friends’,
‘Boredom’ and ‘Hair loss’. As these are not in the PCL, it is unknown
how many adults would endorse them, however it is noteworthy that
they were items that AYAs and clinicians recommended adding when
modifying the adult checklist. The social domain was added for AYAs
and highly endorsed, adults are more likely to endorse items from the
financial domain,32 whereas ‘Bills and finance’ had low endorsement
from AYAs. ‘Loss of meaning or purpose’ and ‘Feeling alone or iso-
lated’ were the two items most likely to differentiate distressed from
non‐distressed AYAs, reflecting perhaps the extraordinary life
disruption a cancer diagnosis brings, including the loss of connection
with friends and lack of opportunity for connection with others going
through a similar experience.
4.1 | Limitations
Whilst the multinational element of this study may minimise biases of
location and context, the countries included are all Western and
English speaking so there are limitations in the generalisability of the
findings. Further validation of this tool in language—appropriate
formats should be sought in non‐English speaking countries and
cultures. Conducting a multinational study brought its own chal-
lenges such as differences in demographic variables and how the
AYA‐NA was administered, which resulted in data being excluded
from some analyses. We were also unable to conduct a sub‐group
analysis to compare cut‐offs between adolescents and young adults
due to insufficient numbers of participants who were under eighteen.
While the HADS is widely accepted as a screening tool for
depression and anxiety in medical settings33 and has been the most
commonly used reference criterion for validating the DT,13 its suit-
ability for use with cancer patients and adolescents has been
questioned.34,35
Finally, the study focused on AYAs within 3 months of diagnosis
and so we cannot comment on distress across the cancer trajectory.
This homogeneity is also a strength of the study as a meta‐analysis in
adults reported variation in DT cut‐off scores at different points in
the cancer trajectory.13
4.2 | Clinical implications
Our findings indicate that a higher cut‐off of 5 (cf. the standard cut‐
off of 4) is more appropriate with this age group, necessitating a small
and significant change in practice for institutions currently using the
adult cut‐off of 4 with AYAs. A cut‐off of 4 would result in specificity
falling below 0.7, which is unacceptably low.27,28 A cut‐off of 5, which
has a higher Youden's Index, will reduce the number of false positives
with relatively little impact on the test's sensitivity (sensitivity = 0.82
for a cut‐off of 5, and 0.90 for a cut‐off of 4, based on the HADS Total
score).
This study provides confidence in the validity and clinical use-
fulness of both elements of the AYA‐POST as a sufficiently accurate,
brief and broad psychosocial screening tool for AYAs recently diag-
nosed cancer. The validation data supports its on‐going use in prac-
tice, to support individual care, guide appropriate resource allocation
within the health sector and facilitate epidemiological population‐
based research in future.
Understanding which items on the AYA‐NA are strongly endorsed
generally, and for those who are identified as distressed, is clinically
helpful in identifying which services to resource, the appropriate mix of
healthcare professional skills and timely intervention. For example,
ensuring that AYAs stay connected with others during their treatment
and are supported in renegotiating their life purpose, is essential.
Likewise, older AYAs and females are more likely to indicate distress
and may require additional, tailored support.
5 | CONCLUSIONS
This study establishes a clinically appropriate cut‐off score of 5 on
the DT for recently diagnosed AYAs, characterises the levels of
distress and identifies the concerns of these AYAs, in a multi‐
institutional, multinational study in primarily English‐speaking coun-
tries. The availability of a validated tool for use with this vulnerable
population will enable health professionals to confidently screen for
distress and unmet needs, thus leading to better support provision
and guidance on service development for AYAs diagnosed with
cancer.
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ENDNOTES
1 Internationally, the age range defined as AYA is varied: it can start as
low as 10 years (e.g., in China) and range as high as 39 years (USA). The
introduction section of this paper will, therefore, by necessity include
publications with various definitions of AYA.
2 The AYA‐POST including the DT and AYA‐NA can be accessed online
at: https://www.canteen.org.au/youth‐cancer/resources/aya‐psychoso-
cial‐care‐manual/.
3 15–24 years in the UK, 15–25 years in Australia, 15–29 years in Canada
and the USA.
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